PolyPeptide Group and Samsung Biologics have entered into a transaction agreement under which Samsung Biologics agreed to make an all-cash public tender offer to acquire all publicly held registered shares of PolyPeptide for CHF 44.31 per share.

The transaction aims to provide PolyPeptide with the resources, investment capacity and strategic platform to pursue the next phase of its growth and innovation, it states. Alongside Samsung Biologics’ global manufacturing scale and track record of operational excellence, PolyPeptide will also benefit from an aligned customer footprint.

“PolyPeptide was built on the dedication of our employees, deep scientific expertise and strong customer focus. After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics’ offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today. At the same time, it represents a transformational opportunity to accelerate our strategic ambitions at a scale we could not reach alone – creating a stronger global partner for customers and a platform uniquely positioned to lead the next phase of growth in peptide-based therapeutics,” says Peter Wilden, Chairman of the Board of Directors of PolyPeptide.

The offer price represents a 40% premium to the undisturbed share price of CHF 31.65, being the last closing price of PolyPeptide’s shares on the SIX Swiss Exchange as of 10 April 2026, which was the last trading day prior to the emergence of market rumors regarding a potential acquisition of PolyPeptide. The offer price represents an approximately 11.6% premium to the volume-weighted average share price over the last 60 trading days prior to the publication of this announcement.

The Board of Directors unanimously recommends that PolyPeptide’s shareholders accept the offer. In reaching its recommendation, the Board, advised by its financial and legal advisors, assessed the offer as part of a competitive process initiated following indications of interests received and which led to proposals from multiple interested parties and against PolyPeptide’s standalone strategic plan, associated funding needs, as well as other strategic alternatives.

The Board’s recommendation is further supported by an independent fairness opinion from IFBC, concluding that the offer price is fair from a financial point of view. The fairness opinion will be published alongside the Board report together with Samsung Biologics’ offer prospectus, the company states.

PolyPeptide’s largest individual shareholder, Draupnir Holding B.V., owning a stake of approximately 55.65% based on total shares outstanding (excluding treasury shares), has been in support of the strategic review process and has committed to tender all of its shares into the offer.

The offer is subject to the satisfaction of customary offer conditions, including a minimum acceptance rate of 66⅔% on a fully diluted share count basis and the receipt of regulatory approvals in certain jurisdictions. Samsung Biologics’ Offer Prospectus, which will contain the full terms and conditions of the offer, is expected to be published no later than August 31, 2026, and the transaction is currently expected to be completed towards the end of 2026. Shareholders of PolyPeptide are encouraged to tender their shares into the offer in the main offer period.

“This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India. We highly value PolyPeptide’s world class employees, industry leading capabilities, and global operational footprint, and look forward to leveraging the complementary strengths of PolyPeptide and Samsung Biologics in our continued growth supporting clients as the CDMO of choice for decades to come,” says John Rim, Chairman of the Board of Directors and CEO of Samsung Biologics.

“We have transformed PolyPeptide into one of the leading focused peptide CDMOs globally, with a rich pipeline, deep exposure to the fast-growing metabolics space, and a marked acceleration in sales growth and profitability. Combining our expertise and innovation with the industrial and financial capabilities of Samsung Biologics will create a formidable new partner to lead the next phase of growth in the peptide CDMO market,” says Juan Jose Gonzalez, CEO of PolyPeptide.